A listing of Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
What is the purpose of this study?The purpose of this study is to research the safety and effectiveness of the combination of Pembrolizumab and ATRA (All-Trans Retinoic Acid) to treat Hodgkin’s lymphoma or B-cell Non-Hodgkin’s lymphoma that has relapsed (cancer has returned). THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent …
What is the purpose of this study?The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Interested in participating? For more …
What is the purpose of this study?2.1 Primary ObjectiveIdentify early axonal damage patterns, and correlate findings with genes, biomarkers, and existing clinically validated clinician neuropathic reporting tools.2.2 Secondary ObjectivesCharacterize the longitudinal pattern of axonal damage in CAYAs with cancer receiving VCR.Investigate the correlation between novel biomarkers of axonal damage and …
What is the purpose of this study?A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or …
What is the purpose of this study?This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with …
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and otherdications.
